A Novel Two-Lipid Signature Is a Strong and Independent Prognostic Factor in Ovarian Cancer

SIMPLE SUMMARY: Most ovarian cancer patients initially show a response to primary treatments, but the development of refractory disease is a major problem. Currently, there are no blood-based prognostic biomarkers, and the prognosis of a patient is determined by the International Federation of Gynec...

Descripción completa

Detalles Bibliográficos
Autores principales: Salminen, Liina, Braicu, Elena Ioana, Lääperi, Mitja, Jylhä, Antti, Oksa, Sinikka, Hietanen, Sakari, Sehouli, Jalid, Kulbe, Hagen, du Bois, Andreas, Mahner, Sven, Harter, Philipp, Carpén, Olli, Huhtinen, Kaisa, Hynninen, Johanna, Hilvo, Mika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067677/
https://www.ncbi.nlm.nih.gov/pubmed/33917079
http://dx.doi.org/10.3390/cancers13081764

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067677/
https://www.ncbi.nlm.nih.gov/pubmed/33917079
http://dx.doi.org/10.3390/cancers13081764

Ejemplares similares